Ignite Creation Date:
2025-12-25 @ 1:30 AM
Ignite Modification Date:
2026-03-05 @ 7:55 AM
Study NCT ID:
NCT02761694
Status:
TERMINATED
Last Update Posted:
2023-05-06
First Post:
2016-04-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)
Sponsor:
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-06-26
Start Date Type:
ACTUAL
Primary Completion Date:
2021-03-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-03-10
Completion Date Type:
ACTUAL
First Submit Date:
2016-04-29
First Submit QC Date:
None
Study First Post Date:
2016-05-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-03-07
Results First Submit QC Date:
None
Results First Post Date:
2022-06-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-02
Last Update Post Date:
2023-05-06
Last Update Post Date Type:
ACTUAL